101 related articles for article (PubMed ID: 16604825)
1. The 5-hydroxytryptamine2A receptor antagonist sarpogrelate hydrochloride inhibits acute platelet aggregation in injured endothelium.
Houkin K; Nakayama N; Nonaka T; Koyanagi I
J Int Med Res; 2006; 34(1):65-72. PubMed ID: 16604825
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic analysis of antiplatelet effect of sarpogrelate hydrochloride and its application to drug dosage regimen--modeling based on reversible inhibition of 5-HT2 serotonergic receptor in the platelet membrane by sarpogrelate hydrochloride and its metabolite].
Shimizu T; Yamada Y; Tashita A; Yamamoto K; Kotaki H; Sawada Y; Iga T
Yakugaku Zasshi; 1999 Nov; 119(11):850-60. PubMed ID: 10590712
[TBL] [Abstract][Full Text] [Related]
3. Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft.
Kodama A; Komori K; Hattori K; Yamanouchi D; Kajikuri J; Itoh T
J Vasc Surg; 2009 May; 49(5):1272-81. PubMed ID: 19233592
[TBL] [Abstract][Full Text] [Related]
4. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
Nakamura K; Kariyazono H; Masuda H; Sakata R; Yamada K
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):391-7. PubMed ID: 11505083
[TBL] [Abstract][Full Text] [Related]
5. Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
Satomura K; Takase B; Hamabe A; Ashida K; Hosaka H; Ohsuzu F; Kurita A
Clin Cardiol; 2002 Jan; 25(1):28-32. PubMed ID: 11808836
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
7. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin.
Nakamura K; Kariyazono H; Moriyama Y; Toyohira H; Kubo H; Yotsumoto G; Taira A; Yamada K
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):513-9. PubMed ID: 10636463
[TBL] [Abstract][Full Text] [Related]
8. Effect of sarpogrelate hydrochloride, a 5-hydroxytryptamine2 receptor antagonist, on allograft arteriosclerosis after aortic transplantation in rats.
Watada S; Harada H; Matsubara K; Obara H; Matsumoto K; Ando N; Kitagawa Y
Transpl Immunol; 2013 Dec; 29(1-4):162-6. PubMed ID: 23851153
[TBL] [Abstract][Full Text] [Related]
9. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
10. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Kobayashi S; Satoh M; Namikoshi T; Haruna Y; Fujimoto S; Arakawa S; Komai N; Tomita N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2008 Apr; 12(2):119-125. PubMed ID: 18175064
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
Kodama A; Komori K; Kajikuri J; Itoh T
J Vasc Surg; 2009 Sep; 50(3):617-25. PubMed ID: 19700096
[TBL] [Abstract][Full Text] [Related]
12. Effects of a 5-HT2A receptor antagonist, sarpogrelate on thermal or inflammatory pain.
Nishiyama T
Eur J Pharmacol; 2005 May; 516(1):18-22. PubMed ID: 15916757
[TBL] [Abstract][Full Text] [Related]
13. The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats.
García-Pedraza JÁ; García M; Martín ML; San Román L; Morán A
Eur J Pharmacol; 2014 May; 731():80-7. PubMed ID: 24675150
[TBL] [Abstract][Full Text] [Related]
14. Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models.
Yamashita T; Kitamori K; Hashimoto M; Watanabe S; Giddings JC; Yamamoto J
Haemostasis; 2000; 30(6):321-32. PubMed ID: 11357001
[TBL] [Abstract][Full Text] [Related]
15. Peripheral 5-HT₁D and 5-HT₇ serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats.
García-Pedraza JÁ; García M; Martín ML; Gómez-Escudero J; Rodríguez-Barbero A; Román LS; Morán A
Eur J Pharmacol; 2013 Aug; 714(1-3):65-73. PubMed ID: 23769743
[TBL] [Abstract][Full Text] [Related]
16. Antinociception in rat by sarpogrelate, a selective 5-HT(2A) receptor antagonist, is peripheral.
Obata H; Saito S; Ishizaki K; Goto F
Eur J Pharmacol; 2000 Sep; 404(1-2):95-102. PubMed ID: 10980267
[TBL] [Abstract][Full Text] [Related]
17. Erythrocyte-protective effect of sarpogrelate hydrochloride (Anplag ®), a selective 5-HT2 receptor antagonist: an in vitro study.
Nakamura K; Kawahito K
J Artif Organs; 2010 Sep; 13(3):178-81. PubMed ID: 20799047
[TBL] [Abstract][Full Text] [Related]
18. A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
Satoh K; Yatomi Y; Ozaki Y
J Thromb Haemost; 2006 Feb; 4(2):479-81. PubMed ID: 16420586
[No Abstract] [Full Text] [Related]
19. Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients.
Nagayama D; Ohira M; Saiki A; Shirai K; Tatsuno I
Int Heart J; 2014; 55(4):337-41. PubMed ID: 24898600
[TBL] [Abstract][Full Text] [Related]
20. Electroencephalographical effects of sarpogrelate hydrochloride versus ticlopidine hydrochloride in elderly patients with peripheral atherosclerosis.
Iwakuma H
J Int Med Res; 2004; 32(3):274-83. PubMed ID: 15174221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
